1 
Version 170726  
 
   
 
DENOSUMAB IN ADDITION TO INTENSE URATE-LOWERING 
THERAPY FOR BONE EROSIONS IN GOUT: A PILOT STUDY 
Clinical Trials Identifier: [STUDY_ID_REMOVED] 
Human Subject Identifier: UAB IRB-160315004 
Date: 07/26/2017 
 
   

2 
Version 170726 1 Contents 
2  Summary ............................................................................................................................... ..................... 4  
3  Background .................................................................................................................... ............................ 5  
4  Rationale for the Study ....................................................................................................... ....................... 5  
5  Research Strategy ............................................................................................................. ........................ 6  
5.1  Study Design .......................................................................................................................................... 6 
5.2  Rationale for Study Design ..................................................................................................................... 6 
6  Outcomes ............................................................................................................................... .................... 6  
6.1  Primary Outcome ............................................................................................................... .................... 6 
6.2  Secondary Outcomes ............................................................................................................ ................. 7 
7  Patient Population ............................................................................................................ .......................... 7  
7.1  Inclusion Criteria ..................................................................................................................................... 7 
7.2  Exclusion Criteria ................................................................................................................................... 8 
8  Study Procedures and Assessments .............................................................................................. ........... 8 
8.1  Screening Visit ....................................................................................................................................... 8 
8.2  Visit 1 (Baseline-Day 0) ...................................................................................................... .................... 9 
8.3  Visit 2 (2-4 weeks) ................................................................................................................................ 10 
8.4  Visit 3 (6-7 months) .............................................................................................................................. 10 
8.5  Visit 4 (26-2 8 weeks) ............................................................................................................................ 10 
8.6  Visit 5 (12 months / Final visit) ............................................................................................................. 10 
9  CT scan of feet: ............................................................................................................................... ......... 12 
10  Informed Consent (IC) Procedures .............................................................................................. ............ 13  
11  Study Medications ............................................................................................................................... ..... 14 
11.1  Denosumab ..................................................................................................................... ..................... 14 
11.1.1  Packaging and Labeling of Clinical Supplies ................................................................................ 15 
11.1.2  Storage and return of Clinical Supplies ......................................................................................... 15 
11.1.3  Denosumab Preparation and Administration ................................................................................ 15 
11.2  Urate Lowering Therapy (ULT) ............................................................................................................. 15 
11.3  Concomitant Medications ..................................................................................................................... 15 
11.4  Gout Flare Prophylaxis ........................................................................................................ ................. 16 
11.5  Gout Flare Treatment ........................................................................................................................... 16 
12  Adverse Events (AE) ............................................................................................................................... . 16 
12.1  Serious AE (SAE) .............................................................................................................. ................... 16 
12.2  Suspected Unexpected Serious Adverse Reaction (SUSARs). ........................................................... 17 
12.3  AE Severity ........................................................................................................................................... 17 
12.3.1  Mild AE .......................................................................................................................................... 17 
3 
Version 170726 12.3.2  Moderate AE ................................................................................................................................. 17 
12.3.3  Severe AE ..................................................................................................................................... 17 
12.4  Adverse Event (AE) Classifications ...................................................................................................... 17 
12.4.1  Expected AE ................................................................................................................................. 17 
12.4.2  Unexpected AE ............................................................................................................................. 17 
12.4.2.1  Related to the research ....................................................................................................... ...... 17 
12.4.2.2  Unrelated to the research .......................................................................................................... 17 
12.4.3  Unanticipated problems involving risks to participants or others (unanticipated problems) .......... 18 
12.5  Relationship to study drugs .................................................................................................................. 18 
12.5.1  Probably related to study drug ................................................................................................ ...... 18 
12.5.2  Possibly related to study drug ................................................................................................ ....... 18 
12.5.3  Unlikely related to study drug ........................................................................................................ 18 
13  Statistical Analyses .......................................................................................................... ........................ 18  
14  Safety Officer ................................................................................................................ ........................... 19  
14.1  Responsibilities .............................................................................................................. ...................... 19 
14.2  Review Process .................................................................................................................................... 19 
14.3  Meeting Format .................................................................................................................................... 20 
14.4  Meeting Mat
erials ............................................................................................................. .................... 20 
14.5  Reports ....................................................................................................................... .......................... 20 
14.6  Confidentiality ............................................................................................................... ........................ 20 
15  Investigational Study Sites ................................................................................................... .................... 20  
15.1  Site Recruitment ................................................................................................................................... 20 
15.2  Participant Recruitment and Consent ................................................................................................... 21 
15.3  Site Monitoring ..................................................................................................................................... 21 
16  Institutional Review Board (IRB) .............................................................................................. ................ 22  
17  Administrative Procedures ..................................................................................................... .................. 22  
17.1  Protocol Amendments .......................................................................................................................... 22 
17.2  Compliance with law, audit, and debarment ......................................................................................... 22 
17.3  Compliance with Financial Disclosure Requirements .......................................................................... 23 
17.4  Publication of results ........................................................................................................ .................... 23 
17.5  Changes in study personnel ................................................................................................................. 23 
18  Bibliography .................................................................................................................. ........................... 23  
 
   
4 
Version 170726 2 Summary  
Title: Denosumab in Addition to Intense Urate-Lowering Therapy for Bone Erosions in Chronic Tophaceous 
Gout Duration: 3 years  Study Site(s): New Zealand - University of Auckl and, USA- University of Alabama at Birmingham 
Approximate number of participants: 20 
Investigators: Angelo L. Gaffo MD, Nicola Dalbeth MD, Kenneth G. Saag MD, MSc.  
Methodology: Open label Randomized multicenter pilot trial to evaluate if the addition of Denosumab to intense 
urate-lowering therapy will lead to a reduction in computer ized tomography (CT) erosion scores in patients with 
radiographic damage caused by gout or chronic tophaceous gout. Protocol – Denosumab and Urate-Lowering Therapy  
 
List Abbreviations, Tables, and Figures 
 Abbreviations : ACR   American College of Rheumatology AE   Adverse Event  BMD    Bone Mineral Density 
CBC                            Complete Blood Count  
CC    Coordinating Center CFR   Code of Federal Regulation CITI   Collaborative Institutional Training Initiative CMP                           Complete Metabolic Profile CT   Computerized Tomography  
CTX   Serum C-Terminal Telopeptide 
DHHS              Department of Health and Human Services EULAR                       European League Against Rheumatism FDA   Food and Drug Administration FWA   Federal Wide Assurance 
GCP   Good Clinical Practice 
HAQ-II                        Health Assessment Questionnaire-II HIPAA   Health Insurance Portability and Accountability Act HIV   Human Immunodeficiency Virus HCG                           Human chorionic gonadotropin  
IC   Informed Consent 
ICF   Informed Consent Form ICH   International Conference on Harmonization  IND   Investigational New Drug IRB   Institutional Review Board IT   Information Technology 
MT                         Metatarsal   
OHRP   Office of Human Research Protections OPG   Osteoprotegerin OP                              Osteoporosis  ONJ                            Osteonecrosis of the Jaw 
PHI   Personal Health Information 
PI   Principal Investigator PII   Personally Identifiable Information PMC   PubMed Central PFS                            Pre-Filled Syringe QA/QC               Quality Assurance/Quality Control 
QOL   Quality of Life 
OHRP                         Office of Human Research Protections RANKL   Receptor Activator Of Nuclear Factor Kappa-B Ligand 
5 
Version 170726 RBC   Red Blood Cells 
RCT   Randomized Clinical Trial SAS   Statistical Analysis System SAP              Statistical Analysis Plan 
SC   Subcutaneous 
SD              Standard Deviation SOP             Standard Operating Procedure SAE                            Serious Adverse Event SUSARs                     Suspected Unexpected Serious Adverse Reaction 
sUA             Serum Uric Acid 
ULA                  Urate-lowering Agent ULT                  Urate-lowering Therapy UAB              University of Alabama at Birmingham VAS                            Visual Analog Scale  
Tables: Table1. Schedule of visits and evaluations 
 
Figures:  Figure 1. Study Design   
 
3 Background  
Bone erosions are a common manifestation and cardinal feature of structural damage in chronic tophaceous 
gout. Management of this destructive and often debilitating gout complication has focused exclusively on urate-
lowering therapy (ULT) but little attention has been given to prevention or reversal of gouty erosions and other 
structural damage caused by gout.1,2 A recently published clinical trial with zoledronic acid failed to show an 
effect in bone erosions among individuals with chronic tophaceous gout, despite improvements in bone mineral density (BMD) and bone turnover markers.
3 However, it is known that increased numbers of osteoclasts in 
patients with tophaceous gout are most likely a result of enhanced osteoclastogenesis as these patients also 
have higher circulating levels of receptor activator of nuclear factor kappa-B ligand (RANKL). Furthermore, 
peripheral blood mononuclear cells and synovial fluid mononuclear cells tak en from patients with erosive gout 
preferentially formed osteoclast-like cells in the pr esence of RANKL. The number of osteoclasts formed 
significantly correlates with the number of tophi in gout patients. 4 
Denosumab (Prolia®) is a fully human monoclonal antibody  with a high affinity (Kd 3 x 10(-12)M) for RANKL 
that can bind and neutralize the activity of human RANKL similar to the action of endogenous osteoprotegerin (OPG). Given the relevance of RANKL in the mechanism of gouty erosions,
4 a central hypothesis of this pilot 
study is that denosumab is more likely to precisely ta rget the mechanism of gouty erosions relative to 
zoledronic acid.  
4 Rationale for the Study  
Since there is no known effective treatment to attenuate or improve structural damage caused by gout, and an 
appreciable effect is not evident with zoledronic acid, we propose a pilot, controlled, proof-of-concept study in 
which denosumab will be added to standard ULT in 20 patients with erosive gout.  
6 
Version 170726 Erosive gout can be a debilitating and deforming arthritis with a profound impact on quality of life (QOL) and 
patient’s productivity. Although many of these effects can be traced to flares and chronic pain, deformities 
induced by tophi are known to compromise joint and limb function. Slowing or reversing erosions induced by 
gout has potential to impact both the patient’s QOL and ability to function.  
The rationale for using denosumab is that we hypothesize the addition of this drug to standard ULT will 
improve structural damage caused by gout through target ing a known mechanism of the gouty erosive process 
(inhibition of RANKL).  
5 Research Strategy  
5.1 Study Design  
This is an open-label, randomized, parallel-group pilot clin ical trial in which 20 participants with at least one 
confirmed conventional radiographic foot bone erosion will be assigned in a 1:1 allocation to one the following 
groups: 
 Denosumab 60 mg administered subcutaneously (SC)  every 6 months for a year + ULT standard of 
care 
OR 
 ULT standard of care  
All subjects will continue on ULT standard of care and will need to have a serum urate level of ≤5 mg/dL (300 
µmol/L) at the time of randomization. Patients will continue prescribed ULT throughout the study. Gout flares 
will be treated as per local practice guidelines. The study design is shown in figure 1. 
5.2 Rationale for Study Design  
 Open-label design : The pilot nature of this study will not allow for a double-blind design, but given 
that the primary outcome is radiographic (which will be interpreted blinded to exposure category) 
this is unlikely to introduce significant bias. 
 Need for active comparator: Prior studies have demonstrated that ULT is important to achieve a 
successful radiographic outcome in gout. In addition, standard of care practice requires patients to 
be on ULT, which is appropriate for a comparator arm. The natural history of gouty erosions will not 
be able to be ascertained for comparison without a comparator arm group.  
 Study duration : 12 months of follow-up will be sufficient for the sensitive computerized tomography 
(CT) scan erosion outcome. 
6 Outcomes 
6.1 Primary Outcome 
The primary outcome in this pilot study will be change in the foot computed tomography (CT) bone erosion 
score from baseline to 12 months. CT images of both f eet will be obtained at the beginning of the study and at 
the 12 month visit. While plain film radiography re mains the standard imaging technique we have chosen CT, 
since it is a more sensitive imaging technique to evaluate changes in bone erosions. 5 6 7 In addition, CT can 
be used to study the effects of gout in areas that are hard to visualize with plain film radiography. The 
participants will be positioned feet first in a supine position with the feet in a plantar flexion position.  Ankles 
and feet will be scanned axially in one helical acquisition. CT bone erosion volume in both feet will be scored using a CT bone erosion scoring method, based on the Rheum atoid Arthritis MRI score (RAMRIS) for erosion, 
as previously validated. 
8 9 This same system was successfully used in our prior study of improvement of gout 
7 
Version 170726 erosions with zoledronic acid. 3 The gout CT bone erosion scoring system includes the following bones for 
erosion on a semi quantitative scale from 0 to 10 in each foot: 1st metatarsal (MT) head, 2nd – 4th MT base, 
cuboid, middle cuneiform, distal tibia (maximum total score 140). All CT scans will be scored at the end of the 
study (paired scans from baseline and year 1 with order known) by a single musculoskeletal radiologist with 
experience in this technique and who is blinded to treatment allocation.3 
 
Figure1: Study Design 
6.2 Secondary Outcomes 
 Decrease in bone reabsorption as measured by serum CTX levels over 12 months 
 Subject reported functional status (disability) by Health Assessment Ques tionnaire-II (HAQ-II) will 
be assessed from baseline over 12 months 
 Subject reported change in physical and mental heal th by Short Form Health Survey (SF-12) scores 
assessed from baseline over 12 months  
 Assessment of pain score by visual analogue scale  (VAS) reported from baseline over 12 months 
7 Patient Population  7.1 Inclusion Criteria 
 Age 30 years or older and able to provide informed consent 
 Diagnosis of gout according to the American College of Rheumatology (ACR) / European League 
Against Rheumatism (EULAR) classification criteria  
 Radiographic foot bone erosion attributable to gout and confirmed by a radiologist or any previous 
x-ray in the past two years showing erosions 
8 
Version 170726  Serum urate of  ≤ 5 mg/dL (300 µmol/L) * on current urate oral lowering therapy (allopurinol, 
probenicid, febuxostat, benzbromorone) 
7.2 Exclusion Criteria 
 Treatment with bisphosphonates in the preceding 2 years 
 Any prior treatment with denosumab (PROLIA) in the past 2 years  
 Women of childbearing potential, who are not currently using birth control, are pregnant, planning to 
become pregnant, or are breast-feeding 
 Men planning to conceive in the next 12 months 
 Unstable systemic medical condition  
 Uncontrolled hyperthyroidism  
 Uncontrolled hypothyroidism  
 History of Addison disease 
 History of osteomalacia 
 History of osteonecrosis of the jaw (ONJ) 
 History of atypical femur fracture  
 History of tooth extraction, jaw surgery, dental implants, or other dental surgery within the prior 6 
months 
 History of anorexia nervosa, bulimia (by history or physical) or obvious malnutrition. 
 Invasive dental work(implants/surgery) planned in the next 2 years 
 History of Paget’s disease of bone 
 Other bone diseases which affect bone metabolism 
 Vitamin D deficiency [25(OH) vitamin D level < 20 ng/mL (<49.9 nmol/L)]†  
 Hypercalcemia 
 Elevated transaminases ≥ 2.0 x upper limit of normal (ULN) 
 Elevated total bilirubin > 1.5x ULN 
 History of any solid organ or bone marrow transplant 
 Malignancy within the last 5 years (except cervical carcinoma in situ  or basal cell carcinoma) 
 Hypocalcemia  
 Estimated glomerular filtration rate < 30 mL/minute/1.73 m^2 
 Current use of any biological therapy (eg. infliximab, etanercept, adalimumab, etc.)   
 Treatment history with pegloticase or another recombinant uricase within 6 months prior to 
randomization. 
 Recipient of an investigational drug within 4 weeks prior to study drug administration or plans to 
take an investigational agent during the study  
*Potential participants could be re-screened after a periord on urate-lowering therapy prescribed by their primary care physician/health care provider;  
† Potential participants could be re-screened after a periord of vita min D supplementation as prescribed by their primary care ph ysician/health care 
provider.   
8 Study Procedures and Assessments 
All study visits and procedures will be performed in facilit ies in the University of Alabama at Birmingham (UAB), 
USA and University of Auckland, New Zealand  
8.1 Screening Visit 
At the screening visit, the study objectives will be explained to potential participants. Participants will have the 
opportunity to ask questions before any protocol-specified screening procedures are initiated and informed 
consent (IC) is obtained. After consent is obtained, a study ID will be assigned. During the screening visit, the 
following procedures will be performed, and information will be obtained to determine eligibility to continue in 
this research study. A copy of the signed and dated informed consent form (ICF) will be provided to the patient. 
The following procedures will be completed during the screening visit: 
 Review inclusion/exclusion criteria 
9 
Version 170726  IC  
 Date of birth 
 Self-reported race/ethnicity 
 Focused medical history  
 Medical conditions that might preclude study participation  
 Assess gout history and symptom severity  
 Medication review  
o Medication history (including use of: over the counter medications (eg. aspirin), other 
prescription medications (eg. gout medications)) 
o Dietary supplement/vitamin use 
 Physical exam includes, but is not limited to 
o Dermatological 
o Chest and cardiac  
o Abdominal 
o Musculoskeletal and nervous system examinations 
o Weight/Height 
 Screening visit laboratory  
o Complete blood count (CBC) with differential 
o Comprehensive metabolic panel (CMP)  
o Serum urate level (sUA) 
o Serum pregnancy test in non-postmenopausal women‡ 
o Vitamin D 
o Intact PTH 
 Review of ULT and gout flare prophylaxis 
‡Defined as a woman:  Age ≥ 55 years, with cessation of menses for 12 or more months;  Ag e < 55 years, but no spontaneous mens es for at least 2 years; Age  < 55 years 
and spontaneous menses within the past 1 year, but currently amenorrheic (eg, spontaneous or secon dary to hysterectomy), AND wi th documented postmenopausal 
gonadotropin levels (luteinizing hormone and follicle-stimulating hormone levels > 40 IU/L) or postmenopausal estradiol levels (< 5 ng/dL) or according  to the definition of 
"postmenopausal range" for the laboratory invo lved; Underwent a bilateral oophorectomy. 
8.2 Visit 1 (Baseline-Day 0) 
Baseline, Visit 1 will occur within 2 weeks of the screening visit and signing of the ICF, and at a time when the 
participant is not having a gout flare or is felt to be at their baseline status of chronic tophaceous gout. Before 
this visit, investigators will contact participants to c onfirm that they are not actively having a gout flare 
according to standard definition. 2 10 If the participant is having a gout flare in the 24-48 hours before the 
scheduled visit, the visit will be postponed for a week. D enosumab will not be administered to participants who 
are actively having a gout flare. During the baseline visit the markers for the study primary and secondary outcomes will be assessed as well as additional data collection needed for safety monitoring. 
 Obtain and record vital signs, including pulse rate, sitting blood pressure, and body temperature 
 Laboratory 
o Blood draw 
 CMP  
 Bone Turnover (serum CTX)  
 Serum banking 
o Urine collection  
 Pregnancy test 
 CT scan of the feet (link to section) 
 Gout therapeutics assessment: review of ULTs and use of medications for gout flare prophylaxis 
and gout flares 
 Review concomitant medications  
 Physical exam includes, but is not limited to 
o Dermatological 
o Chest and cardiac  
o Abdominal 
10 
Version 170726 o Musculoskeletal and nervous system examinations 
o Weight/Height 
 Assessment of functional status (disability) by  Health Assessment Questionnaire-II (HAQ-II), 
physical and mental health by SF-12 scores, and pain score by visual analogue scale (VAS) 
 Administer denosumab in patients randomized to this treatment arm  
Participants will be advised to maintain adequate calcium and vitamin D intake per USDA and DHHS 
guidelines.  
8.3 Visit 2 (2-4 weeks)  
Participants will report 2- 4 weeks following administration of denosumab (Visit 1) to check serum calcium 
levels 
 Laboratory 
o Blood draw 
 Calcium 
8.4 Visit 3 (6-7 months) 
Similar to visit 1, participants will be contacted to make sure that they are not having a gout flare in the 24-48 
hours prior to the scheduled visit.  
 Physical exam includes, but is not limited to 
o Dermatological 
o Chest and cardiac  
o Abdominal 
o Musculoskeletal and nervous system examinations 
o Weight/Height 
 Obtain and record vital signs, including pulse rate, sitting blood pressure, and body temperature 
 Laboratory  
o Blood Draw 
 CBC with differential  
 CMP 
 Bone Turnover (serum CTX)  
 sUA 
 Serum banking 
o Urine collection  
 Pregnancy test 
 Assess AEs 
 Review concomitant medications 
 Gout therapeutics assessment: review of ULTs and use of medications for gout flare prophylaxis 
and gout flares 
 Assessment of functional status (disability) by HAQ-II, physical and mental health by SF-12 scores, 
and pain score by VAS 
 Administer denosumab in patients randomized to this treatment arm  
Participants will be advised to maintain adequate calcium and vitamin D intake per USDA/DHHS and Ministry of Health guidelines. 
8.5 Visit 4 (26-28 weeks) 
Participants will report 2 weeks following denosumab (Visit 3) to check serum calcium levels  
 Laboratory 
o Blood draw 
 Calcium 
8.6 Visit 5 (12 months / Final visit) 
  The following procedures will be completed: 
11 
Version 170726  Obtain and record vital signs, including pulse rate, sitting blood pressure, and body temperature. 
 Laboratory  
o Blood Draw 
 CBC with differential  
 CMP 
 sUA 
 Serum banking 
 Bone Turnover (serum CTX)  
 Assess AEs 
 CT scan of the feet 
 Gout therapeutics assessment: review of ULTSs and use of medications for gout flare prophylaxis 
and gout flares 
 Review concomitant medications 
 Physical exam includes, but is not limited to 
o Dermatological 
o Chest and cardiac  
o Abdominal 
o Musculoskeletal and nervous system examinations 
o Weight/Height 
 Assessment of functional status (disability) by HAQ-II, physical and mental health by SF-12 scores, 
and pain score by VAS  
 Review end of study procedures with the participant 
 
Table1. Schedule of visits and evaluations  
 Screening V1 Baseline V2  
V3 
 V4  
 V5 Final 
 
Months (weeks) -2 Week 0 (2 -4 
Weeks) 6-7 Months (26-28 
Weeks) 12 
Visit description / Study procedures       
Informed consent X      
Inclusion/exclusion criteria X      
Focused medical history and 
physical examination X X  X  X 
Vital signs* X X  X  X 
Pregnancy test § X (serum) X (urine)  X(urine)   
Laboratory       
Blood draw  X X  X  
CBC with diff  X   X  X 
CMP  X X  X  X 
Calcium   X  X  
Serum urate  X   X  X 
Vitamin D   X      
Intact PTH X      
Bone Turnover (serum 
CTX)/Biomarker 
Banking  X  X  X 
Urine Collection   X  X   
CT scan of feet   X    X 
Administer denosumab+   X  X   
Assess AEs and gout flares  
X  X  X 
Review concomitant medications X X  X  X 
12 
Version 170726 Assessment of functional status 
(disability) by HAQ-II ,physical and 
mental health by SF-12 scores , 
and pain score by VAS reported   X  X  X 
CMP = Complete metabolic profile, CBC with diff = Complete blood count with Differentiation, HAQ-II = Health Assessment Questio nnaire-II, VAS = Visual Analog Scale , * 
Includes sitting blood pressure, heart rate, respiratory rate, an d body temperature; + For patients randomized to denosumab, § Serum human chorionic gonadotropin (hCG) 
assessment for premenopausal women will be done at screening visit with urine stick thereafter before each denosumab dose  
 
9 CT scan of feet: 
 
CT images of both feet will be obtained at the beginning and the end of the study (V1 and V5). The participants 
will be positioned supine with the knees bent at 90 and the feet dorsiflexed 45. Both feet will be scanned 
together with the CT gantry vertical. The range covered was from 5 cm above the ankle joint to the ends of the toes. All scans will be performed with the same image protocol of acquisition at 16 x 0.75 mm, reconstructed 
on a bone algorithm, 768 matrix, to 0.8 mm slices with a 0.4 mm increment (kVp 140, 120 mAs/slice). 
Additional reconstructions will be done on a soft tissue algorithm, 512 matrix, also to a 0.8 mm slice with a 0.4 
mm increment. Images will be transferred via encrypted UAB Sharefile portal or via encrypted hard disc 
shipped via courier to the University of Auckland to be read. .  
The CT scans will be analyzed for bone erosions by a trained musculoskeletal radiologists (Anthony Doyle) 
who will be blinded to the clinical details or plain radiographic damage scores. Bone erosion will be assessed 
using reformatted images in the anatomical, axial, sagi ttal and coronal planes. Erosions on CT are defined as 
focal areas of loss of cortex with sharply defined margins, seen in two planes, with cortical break seen in at least one plane. Bone erosion will be scored using a semiquantitative method based on the rheumatoid arthritis MRI scoring system (RAMRIS) [REF]; each bone will be scored separately on a scale from 0 to 10, based on 
the proportion of eroded bone compared with the ‘assessed bone volume’, judged on all available images—0: 
no erosion; 1: 1–10% of bone eroded; 2: 11–20%, etc. For long bones and large tarsal bones, the ‘assessed 
bone volume’ goes from the articular surface (or its best estimated position if absent) to a depth of 1 cm. Bone 
erosion was assessed at 22 bones in each foot (44 bones/patient). These sites are selected to include all 
bones in the foot and ankle except for the great toe distal phalanx and the lesser toe phalanges. The following 
bones will be scored: distal and proximal portions of the fi rst proximal phalanx, first to fifth metatarsal (MT) 
heads, first to fifth MT bases, lateral, middle and medial cuneiforms, navicular, cuboid, anterior process of calcaneus, proximal calcaneus, distal talus, proximal talus and distal tibia. 
Bone erosion score form 
  
  Erosion score (RAMRIS) 
CT scoring system  Visit Baseline Year 1 
   Date of scan      
Right  MTP1 head       
Right  MTP2 base       
Right  MTP3 base       
Right  MTP4 base       
Right  Cuneiform  middle      
Right  Cuboid       
Right  Distal  tibia       
13 
Version 170726            
          
Left  MTP1 head       
Left  MTP2 base       
Left  MTP3 base       
Left  MTP4 base       
Left  Cuneiform  middle      
Left  Cuboid       
Left  Distal  tibia       
RAMRIS scoring 
Bone erosions: each bone is scored separately. The scale is 0–10, based on the proportion of eroded bone 
compared to the "assessed bone volume", judged on all available images—0: no erosion; 1: 1–10% of bone 
eroded; 2; 11–20%, etc. For long bones, the "assessed bone volume" is from the articular surface (or its best 
estimated position if absent) to a depth of 1 cm, and in tarsal bones (cuneiform and cuboid) it is the whole bone 
in the foot 
In addition, erosion scoring will be done in additional bones (not part of study primary outcome) 
 
 
10 Informed Consent (IC) Procedures  
The process of IC will be carried out by one of the study investigators in conjunction with the study 
coordinator/research assistant involved in the screening visit after the participant appears to meet the pre-
screening criteria. During the screening visit, the ICF will be read by the study participant and then each section will be explained by the research study coordinator obtaining consent. The participant will be given as Additional  bones with erosion 
Vis it Bas eline Year 1
Date of scan
Right
RightRightRightRightRightRight
Left
LeftLeftLeftLeftLeftLeftErosion score (RAMRIS)
14 
Version 170726 much time as they need to read and ask questions about th e ICF. The individual or patient’s legally authorized 
representative will be informed that he/she is not obligated to participate in the study and that it is strictly 
voluntary and that he/she may withdraw from the study at any time and that withdrawal of consent will not 
affect his/her subsequent medical treatment or relati onship with the treating physician. The IC process will 
ensure that there is no penalty for not participating in a clinical trial and that treatment will not be compromised if individuals do not participate, or if they cease participation at any time. 
By signing the consent form, the participant authorizes the use of their personal health information (PHI), that 
they understand the study and its benefits and risks, and agree to all other aspects of the study outlined in the 
form. It allows the participant the opportunity to decide whether they want to participate in a study. During this 
process, individuals will be informed of all aspects of the study so that they can make an informed decision. 
Participants will then confirm their willingness to participate in the research study by signing the ICF. 
After the participant has signed the consent form, the Principal Investigator (PI), and the research assistant 
conducting the visit will each sign and date the ICF. A signed version of the consent form will be kept by the 
study staff in the study binder and an additional copy of t he consent form will also be given to the participant to 
keep. 
The ICF contains the following: 
 Disclosure of relevant information to prospective participants about the research 
 The participant’s comprehension of the information 
 The participant’s voluntary agreement to participate in a research study without coercion or undue 
influence 
 Complete disclosure of any appropriate alternative procedures and their risks and benefits 
 Disclosure of the extent of confidentiality that will be maintained 
 Statement of compensation and/or medical treatment available if injury occurs 
 Name, address, and telephone number of the PIs 
If there is a change in any of the study procedures that may affect the participant, the ICF will be revised and 
approved by the Institutional Review Board (IRB). Any participants enrolled in the study prior to a change in 
procedures will sign the amended consent form. Signed consent  forms will be kept as part of the study record 
for at least 7 years after completion of the study. Participants can withdraw their consent at any time by informing the study coordinator. 
11 Study Medications  
11.1 Denosumab  
Denosumab (Prolia®) is a fully human monoclonal antibody  with a high affinity (Kd 3 x 10(-12)M) for RANKL 
that can bind and neutralize the activity of human RANKL, similar to the action of endogenous OPG. The 3-
year data from the randomized, double-blind, placebo controlled, phase III trial demonstrated that denosumab 
treatment reduced the incidence of new vertebral fractures, non-vertebral fractures and hip fractures when 
compared with placebo.
11 In the United States and Canada, denosumab has approvals for indications including 
the treatment of osteoporosis (OP) in postmenopausal women and men at high risk for fracture. In the European Union, denosumab has been approved for the treatment of OP in postmenopausal women at 
increased risk of fracture. 
15 
Version 170726 11.1.1 Packaging and Labeling of Clinical Supplies  
Denosumab will be manufactured by Amgen Inc. Labeli ng and dispensation of study drug will be handled by 
the investigational pharmacies at UAB and University of Auckland. Study drug labeling will be annotated with 
the approved IRB protocol number(s).  
11.1.2 Storage and return of Clinical Supplies 
Investigational clinical supplies will be handled and stored safely and properly, and kept in a secured location to which only the PI and designated staff members have ac cess. Clinical supplies will be dispensed only in 
accordance with the protocol. Study sites will keep accurate records of the clinical supplies received from Amgen, the amount dispensed for each patient, and the amount remaining at the conclusion of the study.  The 
coordinator will mark the label of any vials that are not to be used with a large X, and document the reason for 
rejecting them on the drug accountability log. In accordance with good pharmacy practice, gloves will be worn 
during preparation of the dose. We will maintain an inventory of drug supplies received and dispensed. Upon 
completion or termination of the study, all unused denosumab will be returned to Amgen in the original container or authorized designate. All drug supply returns will be made to the study drug packaging and 
shipment vendor specified in the list of external facilities and personnel. 
11.1.3 Denosumab Preparation and Administration 
Denosumab will be presented as a pre-filled syringe (P FS) of 60 mg. All subjects will receive denosumab 
through a SC route of administration. Denosumab will not  be administered intravenously, intramuscularly, or 
intradermal. All SC injections will be administered by authorized site personnel. Denosumab SC injection will 
be administered as the last procedure after all other study visit procedures have been completed. Prior to 
administration of denosumab it will be brought to room tem perature in original container (allowed to stand ~15 
to 30 minutes); it will not be warmed by any other method. The denosumab solution may contain trace amounts of translucent to white protein particles; how ever, it will not be used if cloudy, discolored (normal 
solution should be clear and colorless to pale yellow), or  contains excessive particles or foreign matter. The 
study staff will avoid vigorous shaking. The study staff will administer via SC injection in the upper arm, upper thigh, or abdomen. The injection will not be administered in the same arm from which blood is drawn. 
11.2 Urate Lowering Therapy (ULT) 
All participants will continue with their ULT (e.g. allopurinol, febuxostat, probenecid, or combination ULT, except pegloticase) at the dosage, which was efficacious to maintain a sUA ≤5 mg/dL (300 µmol/L).   
11.3 Concomitant Medications Concomitant medications are defined as drug or biological products other than the study drug(s) taken by a participant during the clinical trial. This includes other  prescription medications (including preventive vaccines), 
over-the-counter medications, herbal medications, vi tamins, and food supplements. A comprehensive list of 
participant’s concomitant medications will be collected at  baseline and at each visit. This will include the name 
of the drug/vitamin/supplement, dose, route of administration, start and stop dates, and the reason for which the medication was taken. All medications will be listed by participant using the generic name(s) of the drug/vitamin/supplement. AE related to the use of a concomitant drug/vitamin/supplement will be documented 
on the adverse event case report form (CRF). Exampl es of all electronic forms can be found in Manual of 
Operating Procedures; Appendices 1  
Medications that will not be allowed during participation in this study include the following:  
 Alendronte (Fosamax®, Binosto®) 
 Risedronate (Actonel®, Atelvia®) 
 Ibandronate (Boniva®) 
 Zoledronic Acid (Zometa®, Reclast®) 
16 
Version 170726  Pamidronate (Aredia®) 
 Teriparatide (Forteo®) 
 Raloxifene (Evista®)f 
 Pegloticase (Krystexxa®) within the past 6 monhs  
11.4 Gout Flare Prophylaxis  
Gout flare prophylaxis will be left to participant’s doctor or provider in charge of managing gout..  
11.5 Gout Flare Treatment 
Gout flare treatment will be left to participant’s doctor or provider in charge of managing gout. 
12 Adverse Events (AE) 
Definitions below incorporate guidelines provided by the Office of Human Research Protections (OHRP) of the 
Department of Health and Human Services (DHHS) and describes Food and Drug Administration (FDA) 
reporting requirements. 
All AEs will be collected. An AE is any untoward event whether or not considered related to the use of 
denosumab or ULT. Any worsening (i.e. any clinically signi ficant adverse change in frequency or intensity) of a 
preexisting condition which is temporally associated with the use of denosumab or ULT is also considered an 
AE. Abnormal laboratory values or test results constitute AEs only if they induce clinical signs or symptoms or 
require therapy, and are recorded on the AE CRF under the signs, symptoms or diagnosis associated with 
them. Screening conditions will not be considered adver se events; however, worsening of a preexisting 
condition may be considered an AE. We will report all AEs according to, the IRB, Amgen, Inc (per terms of the Safety Data Exchange Agreement), and the appropriate health authority (e.g., Food and Drug Administration 
[FDA]).  
12.1 Serious AE (SAE) 
Any AE occurring at any dose that results in any of the following outcomes:  
 Death  
 Is life-threatening (places the patient, in the view of the Investigator, at immediate risk of death from 
the AE as it occurred) 
 Inpatient hospitalization or prolongation of existing hospitalization (hospitalization is defined as an 
inpatient admission, regardless of length of stay, even if hospitalized as a precautionary measure 
for continued observation) 
 A permanent, persistent, or significant disability (substantial disruption of the ability to conduct 
normal life functions). A medically significant AE that may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in this definition 
 Congenital anomaly/birth defect  
 Other medically important serious event  
Other events not considered to be SAEs:  
 Hospitalization for treatment, which was elective or pre-planned, for a pre-existing condition that did 
not worsen 
 Treatment on an emergency, outpatient basis for an event not fulfilling any of the definitions of 
serious given above and not resulting in hospital admission 
17 
Version 170726 12.2 Suspected Unexpected Serious Adverse Reaction (SUSARs). 
Any adverse drug experience, the specificity or severi ty of which is not consistent with the current 
Investigator’s Brochure. 
12.3 AE Severity  
The assessment of severity will be determined by the investigator and recorded on the electronic case report 
form (eCRF) for AE and  SAE according to the investigator ’s best clinical judgment, taking into consideration 
various factors such as the subject’s report, the physi cian’s observations, and the physician’s prior experience. 
The investigator will assess the individual AE severity using the following scale as defined by Common 
Terminology Criteria for Adverse Events (CTCAE) Version 4.03.12 
12.3.1 Mild AE Awareness of signs or symptoms, but easily tolerated and are of minor irritant type causing no loss of time from normal activities. Symptoms do not require therapy or a medical evaluation; signs and symptoms are 
transient 
12.3.2 Moderate AE 
Events introduce a low level of inconvenience or concern to the participant and may interfere with daily 
activities, but are usually improved by simple ther apeutic measures; moderate experiences may cause some 
interference with functioning 
12.3.3 Severe AE 
Events interrupt the participant’s normal daily activities  and generally require systemic drug therapy or other 
treatment; they are usually incapacitating  
12.4  Adverse Event (AE) Classifications  12.4.1 Expected AE  
The Expected adverse effects of Denosumab could be found in the drug Investigator’s Brochure. We 
are collecting adverse events at every visit. 
12.4.2 Unexpected AE Any AE, the specificity, frequency, or severity of which is not consistent with either: 
The known or foreseeable risk of AEs associated with the procedures involved in the research that are 
described in the protocol-related documents, such as the IRB-approved research protocol, any applicable 
investigator brochure, the current IRB-approved informed consent document, and other relevant sources of 
information, such as product labeling and package inserts; or the expected natural progression of any 
underlying disease or condition of the participant(s) experiencing the AE. 
12.4.2.1 Related to the research  
An event is related to the research if, in the opinion of the investigators, it was more likely than not to be the 
result of the interventions and interactions used in the research or the collection of identifiable private 
information in the research (i.e., there is a reasonable possibility that the event may have been caused by participation in the research). 
12.4.2.2 Unrelated to the research 
An AE is unrelated to the research if, in the opinion of the investigators, the AE is not related to the research 
18 
Version 170726 12.4.3 Unanticipated problems involving risks to participants or others (unanticipated problems)  
Problems that are (1) unexpected (in terms of nature, severity or frequency) given the research procedures 
and the participant population being studied; and (2) suggest that the research places participants or others at 
a greater risk of harm or discomfort related to the research than was previously known or recognized including 
physical, psychological, economic or social harm.  
12.5 Relationship to study drugs 
The determination of the likelihood that the study drug caused the AE will be provided by the study site 
Investigator. The study site Investigator’s signature and date on the source document and eCRF that supports 
the causality noted on the AE form, ensures that a medically qualified assessment of causality was done. The 
assessment of relationship will be reported to the IRB and to the study sponsor (Amgen, Inc per safety data 
exchange agreement) by the study site Investigator according to his/her best clinical judgment. The following 
scale of criteria may be used as a guidance (not all criteria must be present in order to be indicative of a drug 
relationship). 
12.5.1 Probably related to study drug 
 There is evidence of exposure to the study drug 
 The temporal sequence of the AE onset relative to administration of the study drug is reasonable 
 The AE is more likely explained by the study drug than by another cause 
12.5.2 Possibly related to study drug 
 There is evidence of exposure to study drug 
 The temporal sequence of the AE onset relative to administration of the study drug is reasonable 
 The AE could have been due to another equally likely cause 
12.5.3 Unlikely related to study drug 
 There is evidence of exposure to the study drug 
 There is another more likely cause of the AE 
 There is no temporal relationship to study drug 
 
12. Data management 
13 Statistical Analyses 
We intend to use the results of this pilot study to dem onstrate feasibility, preliminary efficacy, and estimate 
potential effect sizes (with its accompanying 95% CI) t hat will lead to future grant submissions using other 
funding mechanisms. The primary outcome will be a change in the foot CT bone erosion score from baseline. 
Mean CT erosion scores at baseline among subjects enrolled in a previous study with zolendronic acid was 
17.7 (SD 11.8)3. By enrolling 20 subjects to be randomized 1:1 we will have 80% power to detect a 16-point 
difference in the erosion score in favor of denosumab with a 5% significance level. However, it was agreed that if we can detect a 4-point erosion score difference over a year in favor of the Denosumab arm it will be 
considered clinically meaningful and will be considered a success for a pilot study, leading to consideration to 
proceed into a larger randomized clinical trial. Due to the positive correlation between the baseline and follow-
up the variance of the change will be smaller in the follow-up than the baseline, thus our power should be 
higher than calculated. Parameters will be analyzed under an intention to treat basis. All dependent variables 
will be analyzed for normality or rendered and transformed if needed. Treatment and usual care will be 
compared by an analysis of covariance (ANCOVA) to test the difference in the change in each of the 
19 
Version 170726 parameters (CT Erosion, quality of life (QOL) indexes, pain scores, bone turnover marker scores) between 
groups, with baseline levels included as covariate. If nor mality assumption is violated, some transformation 
(such as log-transformation) will be applied.  Least squares adjusted means, 95% confidence intervals, and standard error of the means will be presented. For AE indicators Fisher’s exact test will be used to test for 
differences in numbers of participants who experienced at least one event or to compare categorical variables 
at baseline. Given the anticipated very small number of AEs, formal tests of statistical significance may not 
prove meaningful and will be significantly underpowered. We plan to use statistical inference through mean 
cumulative function on adverse event incidence. Student t test will be used to compare treatment groups at baseline 
14 Safety Officer 
As the safety of the study participants is the highest priority for this project we will appoint an independent 
safety officer, without conflict of interest with the study, to be responsible for evaluating the scientific issues 
related to the study. The Safety Officer will receive dat a periodically (e.g. every 12 months) including any pre-
specified time points. The outcome of each patient is the top priority and as such, a process for the ongoing monitoring of results by independent scientists is important to maintain throughout the duration of the project. 
Responsibilities  
The Safety Officer responsibilities are to:  
 Review the research protocol, ICFs and plans for data safety and monitoring  
 Evaluate the progress of the trial, including per iodic assessments of data quality and timeliness, 
recruitment, accrual and retention, participant risk versus benefit, and other factors that can affect 
study outcome 
 Consider factors external to the study when re levant information becomes available, such as 
scientific or therapeutic developments that may have an impact on the safety of the participants or 
the ethics of the trial 
 Review study performance, make recommendations and assist in the resolution of problems 
reported by the PI  
 Protect the safety of the study participants 
 Report on the safety and progress of the trial  
 Make recommendations to the PIs, and, if required, to the FDA concerning continuation, termination 
or other modifications of the trial based on the observed beneficial or AEs of the treatment under 
study; 
 Ensure the confidentiality of the study data and the results of monitoring  
 Assist in the commenting on any problems with study conduct, enrollment, sample size and/or data 
collection 
 The Safety Officer will discharge himself/herself from his/her duties when the last participant 
completes the study 
14.2 Review Process  
At the first meeting the Safety Officer will discuss the protocol, suggest modifications, and establish study 
monitoring guidelines. The Safety Officer, in consultation with the study team, will prepare the agenda to 
address the review of study materials, modifications to  the study protocol and ICF, initiation of the trial, 
reporting of AEs, statistical analysis plan etc.  
Meetings with the Safety Officer will be held twice a year. The study investigators and staff will attend most 
meetings. An emergency meeting may be called at any time by the Safety Officer or by the PI should 
participant safety questions or other unanticipated problems arise. 
20 
Version 170726 Meetings are closed to the public because discussions may address confidential participant data. Meetings 
may be convened as conference calls as well as in-person.   
14.3 Meeting Format 
Meetings will consist of open sessions. Discussion held in all sessions will be confidential. The PI and key 
members of the study team attend the open sessions. Discussion will focus on the conduct and progress of the 
study, including participant accrual, protocol compliance, and problems encountered.  
Each meeting must include a recommendation to continue or to terminate the study and whether the Safety 
Officer has any concerns about participant safety. A recommendation to terminate the study may be made by 
the Safety Officer at any time. The Safety Officer will provide such a recommendation to the PI immediately by 
telephone and email. 
14.4 Meeting Materials  
Report templates will be prepared by the study staff, typica lly the statistician, to be reviewed by the Safety 
Officer at the first meeting.  Format and content of the reports will be finalized and approved at the initial Safety 
Officer meeting, although changes throughout the trial may be requested. The reports will list and summarize 
safety data and describe the status of the study.  All meeting materials will be sent to PI who will forward the 
materials to the Safety Officer at least 7 to 14 days prior to the meeting.  
14.5 Reports  
Reports generally include administrative reports by site that describe participants screened, enrolled, 
completed, and discontinued, as well as baseline characteristics of the study population. Other general 
information on study status may also be presented. Listings of AEs and SAEs as well as any other information requested by the Safety Officer may also be in the open session. The Safety Officer may direct additions and 
other modifications to the reports on a one-time or continuing basis. The reports may also contain data on 
study outcomes, including safety data, and perhaps efficacy data.   
A formal report containing the recommendations for continuation or modifications of the study will be prepared 
by the Safety Officer. It is the responsibility of the PI s to distribute the Safety Officer recommendation to all co-
investigators and to ensure that copies are submitted to the UAB and University of Auckland’s ethics committees. 
14.6 Confidentiality  
All materials, discussions, and proceedings of the Safe ty Officer are completely confidential. Members and 
other participants in SO? Meetings are expected to maintain confidentiality. 
15 Investigational Study Sites 
 University of Alabama at Birmingham, United States  
 University of Auckland, New Zealand 
Approximately 10 participants will be enrolled from each study site. 
15.1 Site Recruitment  
Investigational study sites will be two large academic medical centers. The study site staff will ensure 
participants are consented and randomized in accordance with established good clinical research practices. 
Additionally, site investigators and their staff will be required to have prerequisite human subjects training, and 
will answer study related questions, as needed. 
21 
Version 170726 15.2 Participant Recruitment and Consent 
The site study staff will: 
 Provide participants with adequate information concerning the study procedures, and scope 
 Provide adequate opportunity for the participant to consider all available options 
 Respond to the participant’s questions and concerns 
 Ensure that each participant understands all information provided 
 Confirm that birth control is being used 
 Obtain the participant’s written voluntary consent to participate 
 Sign the consent form as witnesses 
 Provide participants with a copy of the consent form 
 Keep the signed form in the participant’s binder 
 Attempt to schedule an early end of study assessment in the case of study drug discontinuation 
15.3 Site Monitoring  
Since this is a two site study, sites will be monitored by the PIs at each res pective site (UAB or the University 
of Auckland) according to established monitoring standar d operating procedures (SOPs). Study site PIs will 
oversee the study to assure satisfactory data record ing, adherence to the study protocol, Good Clinical 
Practice (GCP), and study medication accounting. UAB and the University of Auckland will monitor recruitment utilizing automated reports generated from the study dat abase. UAB and University of Auckland investigators 
and staff will have meetings monthly to monitor site  recruitment and to determine any intervention for poor 
recruitment. The staff listed in the study roster will be responsible for all aspects of the trial. This includes but is 
not limited to the following: 
 Development of the study protocol 
 Development of the manual of procedures and its maintenance 
 Participant randomization  
 Development and implementation of the data flow and data tracking 
 Development of procedures for data entry, error identification, and error correction 
 AE monitoring and reporting 
 Quality control procedures  
 Submitting for IRB review and approval 
 Creating reports - enrollment, AEs, participant status (e.g., withdrawals) 
 Preparing and sending required reports to the Safety Officer and the IRB 
 Submitting all required reports to the study appointed Safety Officer. 
 Distribution of all changes, updates and policies of above mentioned reports and documents to the 
study appointed Safety Officer.  
 Maintaining the study binder (regulatory and clinical documents) 
 Preparation of all study materials- data tables, recruitment materials, official reports 
 Identifying, recruiting, screening, and enrolling participants 
 Obtaining IC from each participant 
 Protecting participants' rights 
 Collecting study data and following participants through study completion 
 Compliance and accountability of administration of study intervention 
 Communicating questions, concerns, and/or observations to the PIs 
22 
Version 170726 All of the above activities will be carried out by the study’s project coordinators, project managers, and 
research assistants on a weekly basis (or more frequent ly as needed) and monitored by the principal and co-
investigators.  
In the event a problem is identified by either study site PI or staff, a teleconference/webinar will be scheduled 
to review the issue. These teleconferences/webinars w ill include discussions of overall recruitment status and 
identified barriers to recruitment experienced by the site with the study team. Detailed recruitment issues and 
suggestions will be discussed, as well as identified barriers.  
The study will be conducted under the auspices of the IRBs at UAB and the University of Auckland. The 
respective site investigators will ensure that an appropriately constituted IRB that complies with the 
requirements of the current International Conference on Harmonization (ICH)-GCP version or applicable 
regulations will be responsible for the initial and continuing review and approval of the clinical study. Prior to 
initiation of the study, the investigator will forward copies of the protocol, ICF, Investigator's Brochure, 
Investigator's curriculum vitae (if applicable), study advertisements (if applicable), and all other subject-related 
documents to be used for the study to the IRB for its review and approval. Before initiating a study, the site PI will have written and dated full approval from the responsible IRB for the protocol. The investigators will also 
promptly report to the IRB all changes in the study, all unanticipated problems involving risks to human 
subjects or others, and any protocol deviations, to eliminate immediate hazards to subjects.  
16 Institutional Review Board (IRB)  
The study site PI and/or staff will not make any changes  in the study or study conduct without IRB approval, 
except where necessary to eliminate apparent immediat e hazards to the subjects. For minor changes to a 
previously approved protocol during the period covered by  the original approval, it may be possible for the 
study site PI to obtain an expedited review by the IRB as allowed. As part of the IRB requirements for 
continuing review of approved studies, the Investigator s will be responsible for submitting periodic progress 
reports to the IRB (based on the Committee's requirements), at intervals appropriate to the degree of subject 
risk involved but no less than once per year. The study site PI should provide a final report to the IRB following 
study completion. To the maximal extent possible, these functions will be assisted by study personnel at the 
Coordinating Center (CC), the University of Alabama at Birmingham.  
17 Administrative Procedures  
17.1 Protocol Amendments 
Any change that affects the conduct of the study or significa ntly alters the protocol will be made in the form of 
an amendment. Any change or addition to this protocol requires a written protocol amendment that must be 
approved by the CC before implementati on. Amendments significantly affecting the safety of participants, the 
scope of the investigation, or the scientific quality of t he study require additional approval by the IRB. Examples 
of amendments requiring such approval are: 
 An increase in drug dosage or duration of participant exposure  
 A significant change in the study design (e.g. addition of a new immunosuppressive) 
 An increase in the number of study visits and procedures to which participants are exposed 
17.2 Compliance with law, audit, and debarment 
Study site PIs will conduct the study in an efficient and diligent manner and in conformance with this protocol; 
generally accepted standards of GCP; and all applicable federal, state, and local laws, rules and regulations 
23 
Version 170726 relating to the conduct of the clinical study. The study site PIs also agree to allow the Safety Officer, 
IRB/Independent Ethics Committee, and regulatory agencies to inspect and review trial-related documents and 
procedures, and provide for direct access to all study-related source data and documents. The study site PIs 
will not seek reimbursement from patients, their in surance providers, or fr om government programs for 
procedures included as part of the study.  
The study site PIs will prepare and maintain complete and accurate study documentation in compliance with 
GCP standards and applicable federal, state, and local laws, rules and regulations.  
Study documentation will be promptly and fully disclosed by the study site PI upon request for inspection, 
copying, review, and audit at reasonable times by any regulatory agencies. The study site PI agrees to 
promptly take any reasonable steps that are requested by designated representatives as a result of an audit to 
cure deficiencies in the study documentation and CRFs. 
Persons debarred from conducting or working on clinical studies by any court or regulatory agency will NOT be 
allowed to conduct or work on this studies.  
17.3 Compliance with Financial Disclosure Requirements  
The study site PIs will provide accurate financial information to allow submission of complete and accurate certification and disclosure statements as required by US FDA regulations (21 CFR Part 54) and/or New 
Zealand. This requirement also extends to sub-Investigators. 
17.4 Publication of results 
It is mandatory that the first publication will be based on data from both centers that has been analyzed as 
stipulated in the protocol. Participating PIs agree not to present data gathered from one center before the full 
publication, unless formally agreed to by all other PIs. 
17.5 Changes in study personnel 
If there is a change of any personnel listed on the Form FDA 1572, a new form reflecting the change will be completed and forwarded to the IRB along with the new staff member’s signed curriculum vitae, medical 
license (if relevant), and signed financial disclosure statement. 
    
18 Bibliography 
1.Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for 
management of gout. Part 2: therapy and antiinfla mmatory prophylaxis of acute gouty arthritis. Arthritis care & 
research. Oct 2012;64(10):1447-1461. 
2.Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for 
management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to 
hyperuricemia. Arthritis care & research. Oct 2012;64(10):1431-1446. 
24 
Version 170726 3. Dalbeth N, Aati O, Gamble GD, et al. Zoledronate for prevention of bone erosion in tophaceous gout: a 
randomised, double-blind, placebo-controlled trial. Annals of the rheumatic diseases. Jun 2014;73(6):1044-
1051. 
4. Dalbeth N, Smith T, Nicolson B, et al. Enhanced osteoclastogenesis in patients with tophaceous gout: urate 
crystals promote osteoclast development through interactions with stromal cells. Arthritis and rheumatism. Jun 
2008;58(6):1854-1865. 
5.Perez-Ruiz F, Dalbeth N, Urresola A, de Miguel E, Schlesinger N. Gout. Imaging of gout: findings and utility. 
Arthritis Research & Therapy. 06/17 2009;11(3):232-232. 
6. Paparo F, Sconfienza LM, Muda A, et al. [Multimodality imaging of chronic tophaceous gout]. Reumatismo. 
Oct-Dec 2010;62(4):286-291. 
7. McQueen FM, Doyle A, Dalbeth N. Imaging in gout--what can we learn from MRI, CT, DECT and US? 
Arthritis Res Ther. 2011;13(6):246. 
8.Ostergaard M, Peterfy C, Conaghan P, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging 
Studies. Core set of MRI acquisitions, joint pathology  definitions, and the OMERACT RA-MRI scoring system. 
The Journal of rheumatology. Jun 2003;30(6):1385-1386. 
9. Ostergaard M, Edmonds J, McQueen F, et al. An introduction to the EULAR-OM ERACT rheumatoid arthritis 
MRI reference image atlas. Annals of the rheumatic diseases. Feb 2005;64 Suppl 1:i3-7. 
10.Gaffo AL, Schumacher HR, Saag KG, et al. Developing a provisional definition of flare in patients with 
established gout. Arthritis and rheumatism. May 2012;64(5):1508-1517. 
11.Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal 
women with osteoporosis. The New England journal of medicine. Aug 20 2009;361(8):756-765. 
12. Health NIo. Common Terminology Criteria for Adverse Events (CTCAE). In: DHHS, ed. 4.03 ed2010:196. 
 